CAMBRIDGE, Mass., and BEIJING, China, July 03, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that on June 29, 2018, the Compensation Committee of BeiGene’s Board of Directors granted restricted share units for an aggregate of 40,608 American Depositary Shares to 85 new employees under BeiGene’s 2018 Inducement Equity Plan.
The 2018 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by BeiGene or one of its subsidiaries as an inducement material to such individual's entering into employment with BeiGene or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
The restricted share units will vest 25 percent on each anniversary of the grant subject to the employees’ continued employment with BeiGene or one of its subsidiaries. The restricted share units are subject to the terms and conditions of BeiGene’s 2018 Inducement Equity Plan and form of award agreement covering the grant.
About BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,200 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i
Investor Contact
Lucy Li, Ph.D.
+1 781-801-1800
ir@beigene.com
Media Contact
Liza Heapes
+ 1 857-302-5663
media@beigene.com
i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.
Source:
BeiGene, LTD.
